Search

7270 Background: Bexarotene, a specific synthetic retinoid analogue, binds to the α, β, and γ subclass of RXR, providing therapeutic specificity and reduced toxicities in pts with RXR-expressing tu...

7260 Background: Randomized phase III trials suggest that neo-adjuvant cisplatin-based chemotherapy prior to surgery may improve survival in patients (pts) with operable NSCLC. The aim of this open...

5071 Background: The standard therapy for stage III endometrial adenocarcinoma (EAC) has been surgical staging followed by adjuvant radiation therapy. Recent trials have suggested that platinum-bas...

7164 Background: Combined radiochemotherapy is considered the standard treatment for stage III nonsmall-cell lung cancer (NSCLC). We investigated the feasibility and activity of hyperfractionated radiation therapy (Hfx RT) and concurrent low-dose, daily carboplatin (C) and paclitaxel (P) in patients with Stage III NSCLC in a phase II trial. Methods: Sixty-four eligible patients started their treatment on day 1 with 30 mg/sqm of P during a 1-hr infusion. From the day 2 started Hfx RT using 1.3 Gy twice-daily (b.i.d.) to a total of 67.6 Gy and concurrent low-dose daily C, 25 mg/sqm and P, 10 mg/sqm, both given Mondays to Fridays during RT course. Daily P dose was administered using a 1-hr infusion scheduled to start at least 2 hours before the first daily fraction. Daily C was administered as short infusion administered 3–4 hr after the first daily RT fraction (i.e. 1.5–2 hr before the second one). Results: Objective response rate was 83% and included CR in 27 (42%) patients and PR in 26 (41%). Ten (16%) pa...

7151 Background: Proteomics-based approaches are the emerging technologies that attempt to understand the biology of cancer through protein-expression analysis. One of the more widely used approach...

We have reached a new plateau in the management of advanced non–small-cell lung cancer. Randomized trials of chemotherapy versus best supportive care showed us that we can improve survival, 1 and quality-of-life analyses have shown that chemotherapy can improve the daily lives of these patients. 2 The development of new drugs in the 1990s gave us an opportunity to treat a more diverse population of lung cancer patients. Trials have shown we can safely administer chemotherapy to the elderly, those with failing performance, and those with concurrent illness because the newer agents are better tolerated and are effective not only with cisplatin, but also alone or in other well-tolerated combinations. Nonetheless, the recent randomized trial from the Eastern Cooperative Oncology Group (ECOG) reported by Dr. Joan Schiller at the American Society of Clinical Oncology meeting this year forces us to refocus our efforts in advanced non–smallcell lung cancer. 3 This trial with four separate arms of platinum-based chemotherapy failed to identify a clearly superior regimen for advanced disease. Therefore, we must pursue new ideas and new drugs with new mechanisms of action, as demonstrated in the pilot trial reported here by Merchant et al. 4

8044^ Background: The IRESSA Pan Asia Study (IPASS) demonstrated superiority of G vs C/P in 1,217 clinically selected chemonaïve pts in Asia with advanced NSCLC. PFS favored C/P initially then G, likely driven by different outcomes according to EGFR mutation (M) status. We report the planned analyses of 233 recruits in Japan (19% of overall population). Methods: From Mar 06 to Oct 07, chemonaïve, never/light ex-smokers with stage IIIB/IV NSCLC and adenocarcinoma histology were randomized to G 250 mg/day (n=114) or C (AUC 5 or 6)/P (200 mg/m2) (n=119). Primary objective was PFS in ITT population; a treatment by country interaction test (Japan vs other) was performed. Secondary endpoints were overall survival (OS), objective response rate (ORR, RECIST), QoL (FACT-L, TOI), symptom improvement (LCS subscale of FACT-L), and tolerability. Results: PFS results in pts in Japan did not significantly differ from other pts (interaction test p=0.4736). G demonstrated superior PFS compared with C/P (HR 0.69; 95% CI 0.51–0.94; p=0.0191); effect was not constant over time, favoring C/P initially then G. Preliminary OS (25% maturity; follow-up ongoing) was similar for G and C/P (HR 0.89; 95% CI 0.53–1.48). ORR for G was 41% vs 35% for C/P;odds ratio [OR] 1.34; 95% CI 0.78–2.30; p=0.2967. QoL improvement rate (TOI) was 43% for G and 28% for C/P (OR 1.92; 95% CI 1.11–3.34; p=0.0200); QoL (FACT-L 41 vs 43%; OR 0.94; 95% CI 0.56–1.60; p=0.8263) and symptom (LCS 42 vs 46%; OR 0.85; 95% CI 0.50–1.43; p=0.5340) improvement rates were similar for G and C/P. Tolerability profile was more favorable with G than C/P. There were no deaths due to ILD-type events (frequency 1.8% [G] vs 0% [C/P]). Conclusions: Efficacy and safety data for pts in Japan were generally consistent with overall population. G demonstrated improved PFS and ORR, similar OS, higher QoL (TOI) and similar symptom improvement rates, and a more favorable tolerability profile compared with C/P in chemonaïve, never/light ex-smokers with advanced NSCLC and adenocarcinoma histology. In IPASS, EGFR M status appeared to be a strong predictive biomarker for G efficacy compared with C/P. [Table: see text] ASCO Conflict of Interest Policy and Exceptions In compliance with the guidelines established by the ASCO Conflict of Interest Policy (J Clin Oncol. 2006 Jan 20;24[3]:519–521) and the Accreditation Council for Continuing Medical Education (ACCME), ASCO strives to promote balance, independence, objectivity, and scientific rigor through disclosure of financial and other interests, and identification and management of potential conflicts. According to the ASCO Conflict of Interest Policy, the following financial and other relationships must be disclosed: employment or leadership position, consultant or advisory role, stock ownership, honoraria, research funding, expert testimony, and other remuneration (J Clin Oncol. 2006 Jan 20;24[3]:520). The ASCO Conflict of Interest Policy disclosure requirements apply to all authors who submit abstracts to the Annual Meeting. For clinical trials that began accrual on or after April 29, 2004, ASCO's Policy places some restrictions on the financial relationships of principal investigators (J Clin Oncol. 2006 Jan 20;24[3]:521). If a principal investigator holds any restricted relationships, his or her abstract will be ineligible for placement in the 2009 Annual Meeting unless the ASCO Ethics Committee grants an exception. Among the circumstances that might justify an exception are that the principal investigator (1) is a widely acknowledged expert in a particular therapeutic area; (2) is the inventor of a unique technology or treatment being evaluated in the clinical trial; or (3) is involved in international clinical oncology research and has acted consistently with recognized international standards of ethics in the conduct of clinical research. NIH-sponsored trials are exempt from the Policy restrictions. Abstracts for which authors requested and have been granted an exception in accordance with ASCO's Policy are designated with a caret symbol (^) in the Annual Meeting Proceedings. For more information about the ASCO Conflict of Interest Policy and the exceptions process, please visit www.asco.org/conflictofinterest .

7077 Background: Gefitinib (‘Iressa’, ZD1839) enhances tumor radioresponsiveness in preclinical studies, and is approved as monotherapy in non-small-cell lung cancer (NSCLC). The aim was to establi...

Purpose Neoadjuvant chemoradiation (nCRT) is the treatment of choice for patients with locally advanced squamous cell carcinoma of the esophagus (SCC). Today radiation oncologists can choose between two different therapy regimes including chemoradiation with cisplatin and 5-fluoruracil (CDDP/5FU) and chemoradiation analogue to the CROSS-regime with carboplatin and paclitaxel (Carb/TAX). However, there is a lack of studies comparing these regimes, especially for the subgroup of patients with SCC. In this study, we want to compare nCRT with CDDP/5FU and nCRT with Carb/TAX for patients with locally advanced SCC.